TY - JOUR T1 - Asthma management in a specialist setting: Results of a national survey JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2016.PA1049 VL - 48 IS - suppl 60 SP - PA1049 AU - Marta Ferrari AU - Silvia Garuti AU - Fulvio Braido AU - G. Walter Canonica AU - Ilaria Baiardini on behalf of SIMeR A3LTC Y1 - 2016/09/01 UR - http://erj.ersjournals.com/content/48/suppl_60/PA1049.abstract N2 - Background: Asthma management has influence on disease outcomes .Aim: The study was aimed to evaluate the clinical features of asthma patients referring to respiratory diseases surgeries and to register the specialist behavior in managing them.Method: an ad hoc survey was developed by a board of pulmonologists. 20 Italian academic and/or hospital centers were asked to recruit the first 30 consecutive asthma patients attending their clinic for a routine visit in a six-month predefined period.Results: Surveys related to 557 asthma patients were filled. Table 1 reports demographic and clinical data. The scheduled visits were requested by the clinic itself in 82,4% of cases; the visits were follow-up visits in 84,4% of cases, and a first examinations in 15,6 % . 72,7% of the overall population were on treatment with ICS/LABA FDC, while 10.4% of patients were treated with anti-IgE antibody. 114 (20,4%) have been judged by the specialist suffering from severe asthma.There is an association between level of asthma control and changing in treatment (chi square 26,4; p<0.001). Uncontrolled patients (ACT <20) were significantly more likely to underwent to a step up of treatment (odd ratio 15,9).Conclusion: In Italian specialist setting only 20% of patients have severe asthma when judged by the specialist himself. The follow up visits overlook the new patient assessment and follow up scheduling seems planned independently by disease's severity. In about 15% of cases asthma has been judged severe although the high dose of IC/LABA combination was not reached.The study has been endorsed by the Italian Society of Pulmonology with the support of a Boehringer Ingelheim unrestricted grant. ER -